ARCH-backed Autobahn launches with $76M to rebuild myelin and reverse MS
For decades, drugs for multiple sclerosis — and there have been many — have been almost exclusively band-aids: inhibitors designed to halt the damage before it got worse, which it inevitably and irreparably would.
But a couple years ago, Keith Lenden, a serial biotech entrepreneur and a newly-minted partner at ARCH Ventures, drove up to Oregon Health & Science University, where over a series of hour-long conversations, professor Tom Scanlan sketched out a new potential plan of attack.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.